Skip to main content Deutsch

Detail

Markus Mitterhauser
Univ.-Prof. PD Mag pharm Dr Markus Mitterhauser, aHPhHead of Experimental Nuclear Medicine, Director Ludwig Boltzmann Institute Applied Diagnostics

Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: Associate Professor

ORCID: 0000-0003-3173-5272
T +43 1 06767620420
markus.mitterhauser@meduniwien.ac.at

Further Information

Keywords

Molecular Imaging; Nuclear Medicine; Radionuclide Imaging

Research group(s)

Research interests

My main research focus is experimental Nuclear Medicine: the development and validation of molecular probes for diagnosis and therapy stratification. 

Techniques, methods & infrastructure

  • preclinical imaging lab (PIL)
  • nuclear medicine Biolabs
  • Radiopharmacy

Grants

  • new preclinical models for tracer development (2020)
    Source of Funding: FFG (Austrian Research Promotion Agency), industrienahe Dissertationen
    Principal Investigator
  • Patient involvment in Oncology (2020)
    Source of Funding: LBG (Ludwig Boltzmann Gesellschaft), PPIE
    Principal Investigator
  • Dual Isotope Imaging (2019)
    Source of Funding: FFG (Austrian Research Promotion Agency), Industrienahe Dissertationen
    Principal Investigator
  • LBI Applied Diagnostics (2015)
    Source of Funding: LBG (Ludwig Boltzmann Gesellschaft), Institute Call
    Principal Investigator
  • Der Adenosin A3 Rezeptor als neues Target für die onkologische Bildgebung mit PET (2014)
    Source of Funding: FWF (Austrian Science Fund), Stand-Alone Projects
    Principal Investigator
  • Simultaneous PET-MRI of the prostate for improved diagnosis and advanced radiotherapy treatment (2011)
    Source of Funding: Medical University of Vienna, CCC RCG011
    Principal Investigator
  • “[11C]DASB and ADHS (2009)
    Source of Funding: OeNB (Oesterreichische Nationalbank), Anniversary Fund
    Principal Investigator
  • Evaluierung von [18F]FE@SNAP und [11C]SNAP-7941 als Liganden für den MCH1 Rezeptor (2008)
    Source of Funding: FWF (Austrian Science Fund), Stand-Alone Projects
    Principal Investigator
  • Evaluierung von (18F)FE@SUPPY als Ligand für den A3 Rezeptor (2006)
    Source of Funding: FWF (Austrian Science Fund), Stand-Alone Projects
    Principal Investigator
  • Preclinical Evaluation of [18F]FE@CIT (2005)
    Source of Funding: OeNB (Oesterreichische Nationalbank), Anniversary Fund
    Principal Investigator